Jaguar Health Reports Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug CrofelemerAccesswire • Tuesday
Jaguar Health to Report Phase 3 OnTarget Trial Results for Its Cancer Supportive Care Drug Crofelemer on July 23rd and Hold Investor Webcast that MorningAccesswire • 07/18/24
Jaguar Health Reports Approval of All Proposals at June 2024 Annual Meeting of StockholdersAccesswire • 06/21/24
Jaguar Health to Report Pivotal Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer on or Before July 23, 2024Accesswire • 06/12/24
Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Accesswire • 06/07/24
REMINDER: Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate UpdatesAccesswire • 05/13/24
Jaguar Health Announces Submission of Clinical Trial Applications for Crofelemer for the Rare Disease Indications Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome (SBS) in EuropeAccesswire • 05/09/24
Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate UpdatesAccesswire • 05/08/24
Crofelemer, Jaguar Health's Prescription Drug Conditionally Approved by the FDA for Chemotherapy-Induced Diarrhea in Dogs, is the Subject of the Company's Investigational New Animal Drug Application for the Indication of General Diarrhea in DogsAccesswire • 05/06/24
Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Pediatric Gastroenterology Conference in Abu Dhabi and Panel Discussion About Microvillus Inclusion Disease (MVID)Accesswire • 04/29/24
Napo Pharmaceuticals, a Jaguar Health Family Company, to Exhibit at Oncology Nursing Society (ONS) Congress in Support of Company's Expanding Focus on Cancer Supportive CareAccesswire • 04/22/24
Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive CareAccesswire • 04/18/24
Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive CareAccesswire • 04/16/24